Drug intelligence / Profile preview

Lysimachia granules

Development stage: Unknown
Lead developer: Chongqing Kerui Pharmaceutical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Lysimachia granules (also known as Herba Lysimachiae granules) is an approved traditional Chinese medicine (TCM) herbal formulation developed and manufactured by Chongqing Kerui Pharmaceutical. Derived from the plant *Lysimachia christinae* (Herba Lysimachiae), the formulation is enriched in bioactive compounds such as quercetin and kaempferide. It is primarily indicated for clearing damp-heat, promoting diuresis, and treating urinary tract stones (urolithiasis), gallstones (cholelithiasis), jaundice, and urinary tract infections.

Brand names: Jin Gan金甘
Other names: Herba Lysimachiae granulesJinqiancao granulesJinqiancao Keli金钱草颗粒

Beyond the preview

Go deeper on Lysimachia granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lysimachia granules.

Explore the full profile